Sanofi to Get Pipeline Boost from Expanded Regeneron Alliance
Dow Jones15:10
0709 GMT - Sanofi's deal to expand its alliance with U.S. peer Regeneron Pharmaceutical provides a boost to the French company's early-stage drug pipeline, J.P. Morgan analysts write in a research note. The conclusion of the negotiations with Regeneron is positive for Sanofi, the analysts say. Sanofi will pay Regeneron $1 billion upfront, and up to $7 billion subject to certain targets to get access to four new drug candidates invented by its partner. Now that an agreement with Regeneron has been reached, Sanofi investors are likely to switch their focus to the company's moves to strengthen its business through dealmaking, the analysts say. Sanofi shares rise 2%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments